Isoprenaline (hydrochloride)

Isoprenaline (hydrochloride)

• CAS Number: 51-30-9
• UNSPSC Description: Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma[1][2][3][4][5][6].
• Target Antigen: Adrenergic Receptor; Endogenous Metabolite
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease; Endocrinology
• Assay Protocol: https://www.medchemexpress.com/Isoprenaline-hydrochloride.html
• Purity: 99.86
• Solubility: DMSO : 80 mg/mL (ultrasonic)|H2O : ≥ 50 mg/mL
• Smiles: OC1=CC=C(C(O)CNC(C)C)C=C1O.Cl
• Molecular Weight: 247.72
• References & Citations: [1]Degerman E, et al. Evidence that insulin and isoprenaline activate the cGMP-inhibited low-K_m cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci U S A. 1990 Jan;87(2):533-7|[2]Vannucci SJ, et al. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochem J. 1992 Nov 15;288 (Pt 1):325-30.|[3]Delpy E, et al. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol. 1996 Oct;119(3):471-8.|[4]Muller FU, et al. Isoprenaline stimulates gene transcription of the inhibitory G protein alpha-subunit Gi alpha-2 in rat heart. Circ Res. 1993 Mar;72(3):696-700.|[5]Lei M, et al. Modulation of delayed rectifier potassium current, iK, by isoprenaline in rabbit isolated pacemaker cells. Exp Physiol. 2000 Jan;85(1):27-35.|[6]M E Conolly, et al. Metabolism of isoprenaline in dog and man. Br J PharmacolACS Appl Mater Interfaces. 2023 Mar 29.|ACS Appl Mater Interfaces. 2023 Oct 4.|ACS Nano. 2023 Oct 18.|Biochem Biophys Res Commun. 7 January 2022.|Biochem Pharmacol. 2024 May 29:116329.|Biochim Biophys Acta Mol Basis Dis. 2024 Jan 5:167018.|Biofabrication. 2022 Oct 4.|Biomed Pharmacother. 2021 Apr 8;139:111562.|Biomed Pharmacother. 2021, 111531.|Biomolecules. 2022, 12(11), 1574.|bioRxiv. 2020 Jan.|bioRxiv. 2024 Apr 20.|Cell Biol Int. 2021 Jan;45(1):188-197.|Cell Cycle. 2021 Jun 7;1-17.|Cell Death Differ. 2022 Nov 3.|Cell Mol Immunol. 2023 Jan 5.|Cell Rep. 2022 Mar 8;38(10):110468.|Cell Rep. 2019 Dec 3;29(10):2929-2935.e4|Chem Biol Drug Des. 2024 Feb 6.|Chem Eng J. 2024 Sep 1.|Chin Med. 2024 Jun 11;19(1):82.|Circulation. 2018 Jun 5;137(23):2497-2513.|Eur J Pharmacol. 2020 Nov 5;886:173439.|Eur J Pharmacol. 2021 Jun 23;907:174277.|Eur J Pharmacol. 2024 Oct 30:177085.|FASEB J. 2022 Mar;36(3):e22219.|Food Chem Toxicol. 2023 Feb 17;113670.|Food Funct. 2018 Nov 14;9(11):5528-5535. |Front Oncol. 2021 Apr 22;11:665763.|Int Immunopharmacol. 2023 Sep 5;124(Pt A):110876.|iScience. 2023 Jul 19.|J Cardiovasc Transl Res. 2023 Jan 30.|J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. |J Funct Foods. 66 (2020) 1038022.|J Mol Cell Cardiol Plus. 2024 Dec.|J Pharm Anal. 2024 Jan 4.|J Tradit Complement Med. 2023 Jul 12.|Mbio. 2022 Nov 29;e0229722.|Molecules. 2024 Feb 7;29(4):760.|Nat Commun. 2020 Sep 25;11(1):4857.|Nat Prod Commun. 2023, 18(1): 1934578X221144581.|Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1373-1385. |Pharmaceuticals. 2022, 15(1), 73.|Prostate. 2020 Nov;80(15):1328-1340.|Res Sq. 2024 Sep 30.|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2023 Sep 14.|Research Square Print. 2023 Feb 7.|Sci Rep. 2024 Jul 8;14(1):15683.|Science. 2020 Dec 4;370(6521):eaay2002.|Biomed Res-TOKYO. 2023 Jun 1.|Inflammation. 2024 Mar 6.|J Inflamm Res. 2023 Oct 24.|Nutrients. 2023 Mar 9.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched